| Title |
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung CancerHER3-DXd in EGFR TKI–Resistant EGFR-Mutated NSCLC
|
|---|---|
| Published in |
Cancer Discovery, September 2021
|
| DOI | 10.1158/2159-8290.cd-21-0715 |
| Pubmed ID | |
| Authors |
Pasi A. Jänne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu |
X Demographics
The data shown below were collected from the profiles of 87 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 21 | 24% |
| Italy | 6 | 7% |
| France | 4 | 5% |
| Canada | 3 | 3% |
| Spain | 2 | 2% |
| Japan | 2 | 2% |
| Brazil | 2 | 2% |
| Colombia | 2 | 2% |
| United Kingdom | 2 | 2% |
| Other | 6 | 7% |
| Unknown | 37 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 45 | 52% |
| Scientists | 20 | 23% |
| Practitioners (doctors, other healthcare professionals) | 16 | 18% |
| Science communicators (journalists, bloggers, editors) | 6 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 130 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 130 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 17% |
| Other | 12 | 9% |
| Student > Ph. D. Student | 11 | 8% |
| Student > Bachelor | 9 | 7% |
| Student > Postgraduate | 7 | 5% |
| Other | 14 | 11% |
| Unknown | 55 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 23% |
| Biochemistry, Genetics and Molecular Biology | 20 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Agricultural and Biological Sciences | 3 | 2% |
| Chemistry | 3 | 2% |
| Other | 9 | 7% |
| Unknown | 60 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 110. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2024.
All research outputs
#388,750
of 25,765,370 outputs
Outputs from Cancer Discovery
#192
of 4,156 outputs
Outputs of similar age
#9,694
of 437,630 outputs
Outputs of similar age from Cancer Discovery
#6
of 60 outputs
Altmetric has tracked 25,765,370 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,630 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.